Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK medicines agency head

This article was originally published in The Tan Sheet

Executive Summary

Alasdair Breckenridge, chairman of the Medicines Control Agency's Committee on the Safety of Medicines, named chair-designate of UK's Medicines & Healthcare Products Regulatory Agency, Department of Health announces Nov. 28. MHRA will consist of MCA and Medical Devices Agency and will become official in April 2003 (1"The Tan Sheet" June 17, 2002, In Brief). One of Breckenridge's first responsibilities will be to help appoint a chief exec of MHRA; last day to submit applications for the post was Nov. 20...

You may also be interested in...



UK health agency merger

Medicines Control Agency, Medical Devices Agency will merge into single, as-yet-unnamed entity next April due to increasing convergence in drug, medical device fields, Department of Health announces June 13. Systems and processes by which drugs are licensed, medical devices are controlled will not be affected, but merger will include creation of chairman post to serve as agency's authoritative figurehead and oversee strategic management. Agency also will have a chief executive; current MCA Chief Exec Keith Jones, MD, is leaving his post in October...

Facing Shortage, FDA Further Relaxes Face Mask, Face Shield And Respirator Guidance

As the US heads into a COVID-19 storm with grave concerns about the lack of face masks and respirators for health care workers, the FDA has further relaxed federal oversight for such products, giving more responsibility to employers

Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow

FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.

Topics

UsernamePublicRestriction

Register

PS094886

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel